Acasti Pharma Inc. (ACST) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Acasti Pharma Inc.

ACST

NASDAQ

Unprofitable

34M

Biotechnology

Next Earning date - 19 Jun 2025

34M

Biotechnology

Next Earning date - 19 Jun 2025

3.37USD

0.13 ( 4.01%)

Market Closed (as of Oct 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-17%

Earning Acce

Dist 52w H.

Overview Chart

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y 22.39 %

Key Metrics

Market Cap
34.17M
Shares Outstanding
10.14M
Share in Float
4.65M
Dividende
0

Earning Date
19 Jun 2025
Price Target
3.37
Average Volume
33247
Beta
1.523

Range
1.98-3.6
Industry
Biotechnology
Website
https://www.acastipharma.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.62x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-1.4

EPS

How ACST compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ACST

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ACST

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$2.06

-759%

2025-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.66
vs 0.18

Q4.22

N/A

-0.54
vs -0.54

Q1.23

N/A

-0.30
vs -0.24

Q2.23

N/A

-0.34
vs -0.60

Q3.23

N/A

-0.19
vs -0.66

Q4.23

N/A

-0.21
vs -0.54

Q1.24

N/A

-0.18
vs -0.30

Q2.24

N/A

-0.24
vs -0.34

Q3.24

N/A

-0.54
vs -0.19

Q4.24

N/A

-0.55
vs -0.21

Sales Growth

YoY

Current

Estimates

Q1.22

-100%

NA vs 115K

Q2.22

NA vs NA

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

-32000.00 vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

NA vs NA

Q1.24

+100%

NA vs -32000

Q2.24

NA vs NA

Return on Equity

QoQ

Q3.22

-5%

-0.05
vs -0.04

Q4.22

-4%

-0.04
vs -0.05

Q1.23

-43%

-0.43
vs -0.04

Q2.23

-6%

-0.06
vs -0.43

Q3.23

-6%

-0.06
vs -0.06

Q4.23

-4%

-0.04
vs -0.06

Q1.24

-5%

-0.05
vs -0.04

Q2.24

-4%

-0.04
vs -0.05

Institutionnal Ownership

QoQ

Q1.21

20
vs 25

-20%

Q2.21

20
vs 20

Q3.21

2
vs 20

-90%

Q4.21

1
vs 2

-50%

Q1.22

2
vs 1

100%

Q2.22

1
vs 2

-50%

Q4.22

1
vs NA

Q1.23

1
vs 1

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

globenewswire.com

8 hours ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

globenewswire.com

8 hours ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

globenewswire.com

10 hours ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

zacks.com

10 hours ago

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?

globenewswire.com

16 hours ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Company Description

3.37USD

N/A

0.00x

0.62x

0.0

0.0%

$-1.4

$2.06

Earnings Growth

Latest News

$2.06

Company Description

3.37USD

N/A

0.00x

0.62x

0.0

0.0%

$-1.4